JP2010539166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539166A5 JP2010539166A5 JP2010524866A JP2010524866A JP2010539166A5 JP 2010539166 A5 JP2010539166 A5 JP 2010539166A5 JP 2010524866 A JP2010524866 A JP 2010524866A JP 2010524866 A JP2010524866 A JP 2010524866A JP 2010539166 A5 JP2010539166 A5 JP 2010539166A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterated
- nhc
- coor
- nhr
- structural formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229910052805 deuterium Inorganic materials 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 17
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 17
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 15
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 230000000155 isotopic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical class C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 150000003836 berberines Chemical class 0.000 claims description 9
- -1 deuterium Deuterated paroxetine Chemical class 0.000 claims description 8
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical class C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims description 5
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- VGGNVBNNVSIGKG-UHFFFAOYSA-N n,n,2-trimethylaziridine-1-carboxamide Chemical compound CC1CN1C(=O)N(C)C VGGNVBNNVSIGKG-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 0 *C1(*)Oc2cc(OC[C@](CNCC3)[C@@]3c(cc3)ccc3F)ccc2O1 Chemical compound *C1(*)Oc2cc(OC[C@](CNCC3)[C@@]3c(cc3)ccc3F)ccc2O1 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AOBNZDKYCFWNRA-UHFFFAOYSA-N C=[O]C1(O)Oc2ccccc2O1 Chemical compound C=[O]C1(O)Oc2ccccc2O1 AOBNZDKYCFWNRA-UHFFFAOYSA-N 0.000 description 1
- BWIIFMQXXSSPDD-UHFFFAOYSA-N Cc(c(C)c1)cc2c1OC(O)(O)O2 Chemical compound Cc(c(C)c1)cc2c1OC(O)(O)O2 BWIIFMQXXSSPDD-UHFFFAOYSA-N 0.000 description 1
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99356507P | 2007-09-13 | 2007-09-13 | |
| US60/993,565 | 2007-09-13 | ||
| PCT/US2008/010643 WO2009035652A1 (en) | 2007-09-13 | 2008-09-12 | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539166A JP2010539166A (ja) | 2010-12-16 |
| JP2010539166A5 true JP2010539166A5 (enExample) | 2012-11-01 |
| JP5647519B2 JP5647519B2 (ja) | 2014-12-24 |
Family
ID=40116877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524866A Expired - Fee Related JP5647519B2 (ja) | 2007-09-13 | 2008-09-12 | 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8822498B2 (enExample) |
| EP (2) | EP2200997B9 (enExample) |
| JP (1) | JP5647519B2 (enExample) |
| CN (1) | CN101855218A (enExample) |
| AU (1) | AU2008299921B2 (enExample) |
| CA (1) | CA2698808A1 (enExample) |
| MX (1) | MX2010002692A (enExample) |
| WO (1) | WO2009035652A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006275595B2 (en) * | 2005-07-29 | 2012-08-16 | Concert Pharmaceuticals Inc. | Novel benzo [d] [1,3]-dioxol derivatives |
| US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| JP5647519B2 (ja) | 2007-09-13 | 2014-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成 |
| HUE032771T2 (en) * | 2011-05-18 | 2017-10-30 | Concert Pharmaceuticals Inc | Deuterated derivatives of ivacaftor |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| US20120302526A1 (en) * | 2011-05-27 | 2012-11-29 | Regents Of The University Of Colorado, A Body Corporate | Methods for treating post-traumatic stress disorder |
| CN102942554B (zh) * | 2012-11-14 | 2014-05-28 | 广西师范大学 | 胡椒乙胺缩水杨醛及其合成方法和应用 |
| CN102924426B (zh) * | 2012-11-14 | 2014-07-02 | 广西师范大学 | 胡椒乙胺缩5-氯水杨醛及其合成方法和应用 |
| CA2948721C (en) | 2014-05-13 | 2023-03-28 | F. Hoffmann-La Roche Ag | Deuterated compounds and uses thereof |
| CN103980271B (zh) * | 2014-05-30 | 2015-12-02 | 天津长森药业有限公司 | 黄藤素及其类似物的制备方法 |
| CN104059030B (zh) * | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
| CN110179792A (zh) * | 2014-07-29 | 2019-08-30 | 深圳君圣泰生物技术有限公司 | 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用 |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
| AU2016327603B2 (en) | 2015-09-25 | 2021-04-22 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR potentiators |
| CN108602786B (zh) | 2016-02-25 | 2019-04-23 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的噁二唑类化合物及包含该化合物的组合物及其用途 |
| KR101970326B1 (ko) * | 2016-08-05 | 2019-04-18 | 고려대학교 산학협력단 | 당 부가된 엔클로미펜, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| HRP20241608T1 (hr) | 2017-12-01 | 2025-01-31 | Vertex Pharmaceuticals Incorporated | Postupci za proizvodnju modulatora transmembranskog regulatora provodljivosti cistične fibroze |
| CN113735847B (zh) * | 2021-09-10 | 2022-06-07 | 四川大学 | 一种盐酸小檗碱的合成制备方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4585777A (en) * | 1984-02-07 | 1986-04-29 | A/S Ferrosan | (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT |
| US5167948A (en) * | 1987-08-07 | 1992-12-01 | Mallinckrodt Medical, Inc. | Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| US5958429A (en) | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| US5776969A (en) | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| AU735760B2 (en) | 1997-04-24 | 2001-07-12 | Merck Sharp & Dohme Limited | Use of a NK-1 receptor antagonist and an SSRI for treating obesity |
| IT1291320B1 (it) | 1997-05-08 | 1999-01-07 | Borregaard Italia Spa | Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico |
| DE69704679T2 (de) * | 1997-06-10 | 2001-09-13 | Synthon Bv | 4-phenylpiperidin-derivate |
| KR20010030860A (ko) | 1997-10-03 | 2001-04-16 | 캐리 메디컬 코퍼레이션 | 니코틴 리셉터 길항제, 및 항-진정제 또는 항-불안 약물을함유하는 니코틴 중독치료용 조성물 |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| SK13532000A3 (sk) | 1998-03-17 | 2002-07-02 | Pfizer Products Inc. | Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze |
| US20030187269A1 (en) * | 1998-04-17 | 2003-10-02 | Curzons Alan David | Novel process |
| GB9817195D0 (en) * | 1998-08-07 | 1998-10-07 | Smithkline Beecham Plc | Novel process |
| US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| BR9916618A (pt) | 1999-01-28 | 2001-10-23 | Bristol Myers Squibb Co | Compostos heterocìclicos antidepressivos |
| US20030055070A1 (en) | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
| GB9916187D0 (en) | 1999-07-09 | 1999-09-08 | Smithkline Beecham Plc | Novel process |
| IL137937A0 (en) | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| ES2193921T3 (es) * | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US20040229911A1 (en) | 2000-05-17 | 2004-11-18 | Pfizer Inc | New pharmaceutical combinations for NOS inhibitors |
| DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
| EP1181933A3 (en) | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
| US6369051B1 (en) | 2000-07-06 | 2002-04-09 | American Home Products Corporation | Combinations of SSRI and estrogenic agents |
| US20020077323A1 (en) | 2000-07-12 | 2002-06-20 | Mclean Stafford | Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies |
| GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6436938B1 (en) * | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| WO2002085871A2 (en) | 2001-04-04 | 2002-10-31 | Wyeth | Serotonergic agents with long-acting in vivo effects |
| US6656951B2 (en) | 2001-04-24 | 2003-12-02 | Wyeth | 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists |
| WO2002088132A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists |
| US6861427B2 (en) | 2001-04-26 | 2005-03-01 | Wyeth | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists |
| US6780860B2 (en) | 2001-04-26 | 2004-08-24 | Wyeth | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists |
| US6815448B2 (en) | 2001-05-07 | 2004-11-09 | Wyeth | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| CA2459304A1 (en) | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
| EP1450801A4 (en) | 2001-11-27 | 2010-10-27 | Merck Sharp & Dohme | 2-aminoquinoline CONNECTIONS |
| US20050014848A1 (en) | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| PE20040682A1 (es) | 2002-03-13 | 2004-10-07 | Schering Corp | Derivados de ciclobutano como antagonistas de nk1 |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| US20040224943A1 (en) | 2003-02-19 | 2004-11-11 | Leventer Steven M. | Method of lowering body temperature with (R) - 2,3-benzodiazepines |
| EP1641454B1 (en) | 2003-06-27 | 2008-10-01 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| US20050070577A1 (en) | 2003-07-03 | 2005-03-31 | Pfizer Inc. | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist |
| WO2005018541A2 (en) | 2003-07-11 | 2005-03-03 | Pharmacia Corporation | Cox-2 inhibitor and serotonin modulator for treating cns damage |
| US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| EP1660079A2 (en) | 2003-08-22 | 2006-05-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia |
| EP1670460B1 (en) | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| AU2004309365A1 (en) | 2003-12-19 | 2005-07-14 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| WO2005107716A1 (en) | 2004-03-25 | 2005-11-17 | Cadila Healthcare Limited | Controlled release paroxetine-containing tablets based on a core and a coating |
| FR2869033B1 (fr) | 2004-04-20 | 2006-06-02 | Rhodia Chimie Sa | Procede de preparation de methylenedioxybenzene |
| US20050266082A1 (en) | 2004-05-26 | 2005-12-01 | Patel Satishkumar A | Preparation of stable paroxetine HC1 ER tablets using a melt granulation process |
| KR100920856B1 (ko) | 2004-11-30 | 2009-10-09 | (주)아모레퍼시픽 | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 |
| JP5020931B2 (ja) | 2005-03-14 | 2012-09-05 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | 経口薬剤送達システム |
| KR20070009934A (ko) | 2005-07-16 | 2007-01-19 | 주식회사 씨티씨바이오 | 염산 파록세틴 서방정 및 이의 제조방법 |
| US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| KR20080047375A (ko) * | 2005-07-29 | 2008-05-28 | 콘서트 파마슈티컬즈, 인크. | 약제 화합물 |
| AU2006275595B2 (en) * | 2005-07-29 | 2012-08-16 | Concert Pharmaceuticals Inc. | Novel benzo [d] [1,3]-dioxol derivatives |
| AU2006274565B2 (en) | 2005-08-02 | 2012-05-17 | Lupin Limited | Novel controlled release compositions of selective serotonin reuptake inhibitors |
| US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| US7598273B2 (en) | 2005-10-06 | 2009-10-06 | Auspex Pharmaceuticals, Inc | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| US20090291958A1 (en) | 2006-06-08 | 2009-11-26 | Auspex Pharmaceuticals, Inc. | Substituted PDE5 inhibitors |
| WO2008016677A2 (en) | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| EP2059241A1 (en) * | 2006-09-05 | 2009-05-20 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| JP5647519B2 (ja) | 2007-09-13 | 2014-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成 |
| US20110257260A1 (en) * | 2009-07-21 | 2011-10-20 | Auspex Pharmaceuticals, Inc. | 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor |
-
2008
- 2008-09-12 JP JP2010524866A patent/JP5647519B2/ja not_active Expired - Fee Related
- 2008-09-12 US US12/283,621 patent/US8822498B2/en not_active Expired - Fee Related
- 2008-09-12 CA CA2698808A patent/CA2698808A1/en not_active Abandoned
- 2008-09-12 AU AU2008299921A patent/AU2008299921B2/en not_active Ceased
- 2008-09-12 EP EP08830527.1A patent/EP2200997B9/en not_active Not-in-force
- 2008-09-12 CN CN200880110558A patent/CN101855218A/zh active Pending
- 2008-09-12 EP EP13185607.2A patent/EP2727915B1/en not_active Not-in-force
- 2008-09-12 WO PCT/US2008/010643 patent/WO2009035652A1/en not_active Ceased
- 2008-09-12 MX MX2010002692A patent/MX2010002692A/es not_active Application Discontinuation
-
2014
- 2014-07-24 US US14/340,143 patent/US9315483B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539166A5 (enExample) | ||
| JP7759910B2 (ja) | がんを処置するための組合せ治療 | |
| JP6046710B2 (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物 | |
| AU2020203706B2 (en) | Compositions and methods for treating proliferation disorders | |
| JP6511430B2 (ja) | がんの治療のための化合物および組成物 | |
| JP3457490B2 (ja) | 置換されたヘテロ環誘導体 | |
| CN1138774C (zh) | 取代的6,6-杂-双环衍生物 | |
| JP2008530099A5 (enExample) | ||
| JP2013530150A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| WO2017132518A1 (en) | Combination therapy for treating cancer | |
| JP2015501820A5 (enExample) | ||
| JP2008518900A5 (enExample) | ||
| JP2007514691A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2013540712A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| JP2023528394A (ja) | 大環状ｊａｋ阻害剤およびその適用 | |
| JP2009533417A5 (enExample) | ||
| JP2004517088A5 (enExample) | ||
| JP2012036221A5 (enExample) | ||
| WO2011047315A1 (en) | Subsitituted benzimidazoles | |
| JPWO2019213470A5 (enExample) | ||
| CN107108604B (zh) | 制备三环内酰胺化合物的方法 |